Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.70001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Daichi Yamaguchi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan. Hauptthemen laut MEDLINE: Cephalosporins, Anti-Bacterial Agents, Cefiderocol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shionogi.
Abstract (Originalsprache)
When planning pediatric clinical trials, optimizing the sample size of neonates/infants is essential because it is difficult to enroll these subjects. In this simulation study, we evaluated the sample size of neonates/infants using a model‐based optimal approach for identifying their pharmacokinetics for cefiderocol. We assessed the usefulness of data for estimation performance (accuracy and variance of parameter estimation) from adults and the impact of data from very young subjects, including preterm neonates. Stochastic simulation and estimation were utilized to assess the impact of sample size allocation for age categories in estimation performance for population pharmacokinetic parameters in pediatrics. The inclusion of adult pharmacokinetic information improved the estimation performance of population pharmacokinetic parameters as the coefficient of variation (CV) range of parameter estimation decreased from 4.9%–593.7% to 2.3%–17.3%. When sample size allocation was based on the age groups of gestational age and postnatal age, the data showed 15 neonates/infants would be necessary to appropriately estimate pediatric pharmacokinetic parameters (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology & Pharmacokinetics, Shionogi & Co., Ltd., Osaka, Japan.
- Pharmacokinetics/Pharmacodynamics & Pharmacometrics, Japan Drug Development & Medical Affairs, Eli Lilly Japan K.K, Kobe, Japan.
ORCID-Profile: Daichi Yamaguchi
Förderung
- Shionogi
Zitieren
APA
Yamaguchi, D., Katsube, T., & Wajima, T. (2024). Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70001
Vancouver
Yamaguchi D, Katsube T, Wajima T. Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.70001
BibTeX
@article{Yamaguchi2024,
author = {Yamaguchi, Daichi and Katsube, Takayuki and Wajima, Toshihiro},
title = {Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.70001}
}
EUVIMED